BioStock: Aptahem’s CEO on clinical studies in 2022

When sepsis company Aptahem recently received its European patent and thus strengthened the protection for the drug candidate Apta-1 in eleven European countries, it was the culmination of a news-intensive 2021. Aptahem’s CEO Mikael Lindstam will soon be able to note the preclinical program as completed with the intention of starting the first human studies with Apta-1 in 2022. BioStock contacted Lindstam to get his thoughts on 2021 and hear his expectations for 2022.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2021/12/aptahems-ceo-on-clinical-studies-in-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/